nach oben

Journal of Clinical Immunology

Erschienen in:

01.09.2009

Expression of CD62L on Donor CD4⁺ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation

verfasst von: Ying-Jun Chang, Xiang-Yu Zhao, Ming-Rui Huo, Xiao-Jun Huang

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study was to investigate the association of donor CD4⁺ T cells expressing CD62L with transplant outcomes.

Materials and Methods

We report a prospective analysis of 31 patients who were treated with a Bu/Cy regimen, followed by unmanipulated blood and marrow transplantation.

Results

Median number (range) of CD4⁺CD62L⁺, CD4⁺CD45RA⁺CD62L⁺, and CD4⁺CD45RO⁺CD62L⁺ cells infused were 0.31(0.05–1.10)×10⁸/kg, 0.22(0.03–0.95)× 10⁸/kg, and 0.17(0.01–0.81)×10⁸/kg, respectively. The incidence of grades II to IV aGVHD was 36%. In a multivariate analysis, infusion of >0.22 × 10⁸ CD4⁺CD45RA⁺CD62L⁺ cells infused/kg increased the risk of grades II to IV aGVHD (HR = 4.741, 95% CI = 1.037–21.662, P = 0.045). Thirteen of 31 patients experienced cGVHD, the risk of cGVHD was increased in patients receiving >0.45 × 10⁸ CD4⁺CD45RA⁺ cells infused/kg (HR = 4.614, 95% CI = 1.265–16.829, P = 0.021).

Conclusion

Our results suggest that a high cell dose of CD4⁺CD45RA⁺CD62L⁺ cells increase the incidence of grades II–IV aGVHD. A high number of CD4⁺CD45RA⁺ cells infused were associated with increased risk of cGVHD in our transplant settings.

Holler E. Progress in acute graft versus host disease. Curr Opin Hematol. 2007;14:625–31. doi:10.1097/MOH.0b013e3282f08dd9.PubMedCrossRef

Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–91.PubMed

Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73. doi:10.1182/blood-2005-05-2146.PubMedCrossRef

Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–7. doi:10.1038/sj.bmt.1705445.PubMedCrossRef

Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105:4191–9. doi:10.1182/blood-2004-12-4726.PubMedCrossRef

Eyrich M, Burger G, Marquardt K, et al. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers. Biol Blood Marrow Transplant. 2005;11:371–82. doi:10.1016/j.bbmt.2005.02.002.PubMedCrossRef

Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109:2649–56. doi:10.1182/blood-2006-08-044529.PubMedCrossRef

Tanaka T, Ohtsuka Y, Yagita H, Shiratori Y, Omata M, Okumura K. Involvement of alpha 1 and alpha 4 integrins in gut mucosal injury of graft-versus-host disease. Int Immunol. 1995;7:1183–9. doi:10.1093/intimm/7.8.1183.PubMedCrossRef

Sato T, Habtezion A, Beilhack A, Schulz S, Butcher E, Thorlacius H. Short-term homing assay reveals a critical role for lymphocyte function-associated antigen-1 in the hepatic recruitment of lymphocytes in graft-versus-host disease. J Hepatol. 2006;44:1132–40. doi:10.1016/j.jhep.2005.11.042.PubMedCrossRef

10.

Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L + subpopulation of CD4 + CD25 + regulatory T cells protects from lethal acute GVHD. Blood. 2005;105:2220–6. doi:10.1182/blood-2004-05-2044.PubMedCrossRef

11.

Li B, New JY, Tay YK, et al. Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion. Scand J Immunol. 2004;59:464–8. doi:10.1111/j.0300-9475.2004.01414.x.PubMedCrossRef

12.

Petrovic A, Alpdogan O, Willis LM, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 2004;103:1542–7. doi:10.1182/blood-2003-03-0957.PubMedCrossRef

13.

Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood. 1995;85:2607–18.PubMed

14.

Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107:1703–11. doi:10.1182/blood-2005-08-3445.PubMedCrossRef

15.

Li B, New JY, Yap EH, Lu J, Chan SH, Hu H. Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease. Eur J Immunol. 2001;31:617–24. doi:10.1002/1521-4141(200102)31:2<617::AID-IMMU617>3.0.CO;2-D.PubMedCrossRef

16.

Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins—potential pharmacological targets? Drug Discov Today. 2006;11:1034–40. doi:10.1016/j.drudis.2006.09.004.PubMedCrossRef

17.

Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:2–8. doi:10.1016/j.bbmt.2005.09.015.PubMedCrossRef

18.

Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. Blood. 2008;111:2919–28. doi:10.1182/blood-2007-09-112789.PubMedCrossRef

19.

Anderson BE, Taylor PA, McNiff JM, et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood. 2008;111:5242–51. doi:10.1182/blood-2007-09-107953.PubMedCrossRef

20.

Xu LP, Huang XJ, Liu KY, et al. Allogenic stem cell transplantation from genotypically HLA-identical siblings for 30 patients with myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi. 2006;27:518–21.PubMed

21.

Dong L, Wu T, Zhang MJ, Gao ZY, Lu DP. CD3 + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant. 2007;13:1515–24. doi:10.1016/j.bbmt.2007.09.007.PubMedCrossRef

22.

Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol. 2007;17:193–7. doi:10.1016/j.trim.2006.10.002.PubMedCrossRef

23.

Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature. 1992;360:264–5. doi:10.1038/360264a0.PubMedCrossRef

24.

Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. doi:10.1097/00007890-197410000-00001.PubMedCrossRef

25.

Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.PubMed

26.

Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17. doi:10.1016/0002-9343(80)90380-0.PubMedCrossRef

27.

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706. doi:10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O.PubMedCrossRef

28.

MacDonald KP, Rowe V, Filippich C, et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood. 2003;101:2033–42. doi:10.1182/blood-2002-05-1529.PubMedCrossRef

29.

Sugimori N, Nakao S, Yachie A, et al. Administration of G-CSF to normal individuals diminishes L-selectin + T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin- T cells. Bone Marrow Transplant. 1999;23:119–24. doi:10.1038/sj.bmt.1701552.PubMedCrossRef

30.

Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant. 1990;6:283–9.PubMed

31.

Rocha V, Carmagnat MV, Chevret S, et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. Exp Hematol. 2001;29:1347–52. doi:10.1016/S0301-472X(01)00737-8.PubMedCrossRef

32.

Foster AE, Marangolo M, Sartor MM, et al. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood. 2004;104:2403–9. doi:10.1182/blood-2003-12-4431.PubMedCrossRef

33.

Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ. Transfer of allogeneic CD62L⁻ memory T cells without graft-versus-host disease. Blood. 2004;103:1534–41. doi:10.1182/blood-2003-08-2987.PubMedCrossRef

34.

Carpenter PA. Late effects of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21:309–31. doi:10.1016/j.beha.2008.02.016.PubMedCrossRef

35.

Xystrakis E, Bernard I, Dejean AS, Alsaati T, Druet P, Saoudi A. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol. 2004;34:408–17. doi:10.1002/eji.200324528.PubMedCrossRef

36.

Chen SH, Li X, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol. 2004;79:178–84. doi:10.1532/IJH97.A10227.PubMedCrossRef

37.

Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica. 2004;89:1517–24.PubMed

38.

Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767–72. doi:10.1182/blood-2007-07-097543.PubMedCrossRef

39.

Curti A, Ratta M, Corinti S, et al. Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood. 2001;97:2758–63. doi:10.1182/blood.V97.9.2758.PubMedCrossRef

40.

Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol. 2002;30:495–501. doi:10.1016/S0301-472X(02)00785-3.PubMedCrossRef

41.

Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8 + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892–900. doi:10.1182/blood-2003-01-0150.PubMedCrossRef

Titel: Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation
verfasst von: Ying-Jun Chang
Xiang-Yu Zhao
Ming-Rui Huo
Xiao-Jun Huang
Publikationsdatum: 01.09.2009
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2009
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9293-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Expression of CD62L on Donor CD4⁺ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation

Abstract

Introduction

Materials and Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Materials and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2009

Osteoimmunology: Crosstalk Between the Immune and Bone Systems

Sequential Changes in Serum Cytokines Reflect Viral RNA Kinetics in Target Organs of a Coxsackievirus B Infection in Mice

Clinico-immunologic Study on Immunotherapy with Mixed and Single Insect Allergens

siRNA Knockdown of PD-L1 and PD-L2 in Monocyte-Derived Dendritic Cells only Modestly Improves Proliferative Responses to Gag by CD8+ T Cells from HIV-1-Infected Individuals

Interleukin 18 Promoter Variants (−137G>C and −607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response

Modulation of the Proteome of Peripheral Blood Mononuclear Cells from HIV-1-Infected Patients by Drugs of Abuse

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin